Population characteristics associated with the use of prostate biopsy are poorly understood. We described the use of diagnostic prostate biopsy and subsequent biopsy outcomes in a population-based Australian cohort.
There is a need to improve the treatment of prostate cancer (PCa) and reduce treatment side effects. Vascular-targeted photodynamic therapy (VTP) is a focal therapy for low-risk low-volume localised PCa, which rapidly disrupts targeted tumour vessels.
We analyzed the efficacy and mechanistic interactions of PARP inhibition (PARPi) (olaparib) and CDK4/6 inhibition (CDK4/6i) (palbociclib or abemaciclib) combination therapy in castration-resistant prostate cancer (CRPC) and neuroendocrine prostate cancer (NEPC) models.
To determine whether sub-classification of positive surgical margins increases predictive ability for biochemical recurrence and aids clinical decision making in patients undergoing radical prostatectomy.
Perineal urethrostomy (PU) is often the definitive form of urinary diversion in patients with locally-advanced or anatomically unfavorable penile cancer (PC) requiring total penectomy. Here, we report post-operative PU-related complications and PU stenosis rates after total penectomy with PU in a large multicenter cohort of PC patients.
Transurethral resection of bladder tumor (TURBT) is a fundamental but challenging step in the diagnosis and treatment of non-muscle invasive bladder cancer (NMIBC). The first- and second-look TURBT are central in the management of T1 tumors.
{{header-clinical-trials-navigation}} PSMAfore: A Phase III, Open-label, Multi-Center, Randomized Study Comparing 177Lu-PSMA-617 vs. a Change of Androgen Receptor-directed Therapy in the Treatment of Taxane Naïve Men With Progressive Metastatic Castrate Resistant Prostate Cancer Condition: Prostatic Neoplasms Study Type: Interventional Clinical Trials Identifier NCT 8-digits: NCT04689828 Sponsor: Novartis Pharmaceuticals Phase: Phase 3 Eligibility: Age: minimum 18 Years […]
{{header-clinical-trials-navigation}} An Open-label, Randomized, Phase III Study Comparing 177Lu-PSMA-617 in Combination With Standard of Care, Versus Standard of Care Alone, in Adult Male Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC) Condition: Prostatic Neoplasms Study Type: Interventional Clinical Trials Identifier NCT 8-digits: NCT04720157 Sponsor: Novartis Pharmaceuticals Phase: Phase 3 Eligibility: Age: minimum 18 Years maximum […]
{{header-clinical-trials-navigation}} A Randomized Phase II Study of 177 LuPSMA-617 vs Docetaxel in Patients With Metastatic Castration-Resistant Prostate Cancer and PSMA-Positive Disease Condition: Prostate Cancer Study Type: Interventional Clinical Trials Identifier NCT 8-digits: NCT04663997 Sponsor: Canadian Cancer Trials Group Phase: Phase 2 Eligibility: Age: minimum 18 Years maximum N/A Gender: Male Inclusion Criteria: Histological evidence of […]
{{header-clinical-trials-navigation}} Study of the Dosimetry, Safety and Potential Benefit of 177Lu-PSMA-617 Radionuclide Therapy Prior to Radical Prostatectomy in Men With High-risk Localised Prostate Cancer Condition: Prostatic Neoplasms Study Type: Interventional Clinical Trials Identifier NCT 8-digits: NCT04430192 Sponsor: Peter MacCallum Cancer Centre, Australia Phase: Phase 1/Phase 2 Eligibility: Age: minimum 18 Years maximum N/A Gender: Male […]
